In chronic kidney disease, retained uremic toxins and sustained NF-κB activation actively suppress the kidney's autonomous CLOCK:BMAL1 circadian oscillator — the same machinery that coordinates glomerular filtration, tubular electrolyte handling, and cellular repair. This suppression is compounded by progressive attenuation of nocturnal melatonin secretion, severing a critical hormonal entrainment signal. Melatonin's proposed therapeutic action spans at least six molecular nodes: MT1/MT2 receptor signaling, RORα nuclear receptor activation, Nrf2/HO-1 antioxidant induction, NF-κB and NLRP3 inflammasome restraint, TGF-β1/Smad2/3 fibrogenesis suppression, and SIRT1-linked clock regulation.
The circadian-CKD axis represents genuinely underexplored territory. Most nephrology research has focused on hemodynamic and fibrotic pathways while treating sleep disruption as a symptom rather than a mechanistic contributor. The self-reinforcing cycle described here — where CKD breaks the clock, and clock disruption accelerates CKD — reframes chronobiology as a therapeutic entry point, not just a biomarker domain. However, this remains a review-level synthesis: no new clinical or animal data are presented, and the authors explicitly acknowledge that melatonin's renoprotective effect in humans is unproven beyond surrogate endpoints in small hemodialysis cohorts. Melatonin's favorable safety profile and low cost make it a pragmatic trial candidate, but the mechanistic elegance of this framework should not be mistaken for clinical validation. Adequately powered, randomized trials measuring GFR trajectory are the essential next step before any clinical translation.
